These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The utility of Zhang Q; Xi Y; Li D; Yuan Z; Dong J J Orthop Surg Res; 2020 Jun; 15(1):229. PubMed ID: 32571371 [TBL] [Abstract][Full Text] [Related]
3. Can 18F-FDG PET/CT alone or combined with radiology be used to reliably grade cartilage bone neoplasms for surgical decision making? Gundavda MK; Agarwal MG; Singh N; Gupta R; Reddy R; Bary A Nucl Med Commun; 2022 Feb; 43(2):220-231. PubMed ID: 34678831 [TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
5. F-18 FDG PET differentiation of benign from malignant chondroid neoplasms: a systematic review of the literature. Subhawong TK; Winn A; Shemesh SS; Pretell-Mazzini J Skeletal Radiol; 2017 Sep; 46(9):1233-1239. PubMed ID: 28608242 [TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT in Diagnostic and Prognostic Evaluation of Patients With Suspected Recurrence of Chondrosarcoma. Vadi SK; Mittal BR; Gorla AKR; Sood A; Basher RK; Sood A; Kakkar N; Sen RK Clin Nucl Med; 2018 Feb; 43(2):87-93. PubMed ID: 29261626 [TBL] [Abstract][Full Text] [Related]
7. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors. Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363 [TBL] [Abstract][Full Text] [Related]
8. Can 18F-FDG PET/CT diagnose malignant change in benign chondroid tumors? Purandare NC; Puranik A; Shah S; Agrawal A; Puri A; Gulia A; Nayak P; Rekhi B; Rangarajan V Nucl Med Commun; 2019 Jun; 40(6):645-651. PubMed ID: 30921251 [TBL] [Abstract][Full Text] [Related]
9. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446 [TBL] [Abstract][Full Text] [Related]
10. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma. Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376 [TBL] [Abstract][Full Text] [Related]
11. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma. Liu Y Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435 [TBL] [Abstract][Full Text] [Related]
12. Is Needle Biopsy Clinically Useful in Preoperative Grading of Central Chondrosarcoma of the Pelvis and Long Bones? Roitman PD; Farfalli GL; Ayerza MA; Múscolo DL; Milano FE; Aponte-Tinao LA Clin Orthop Relat Res; 2017 Mar; 475(3):808-814. PubMed ID: 26883651 [TBL] [Abstract][Full Text] [Related]
13. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas. Li DL; Xu YK; Wang QS; Wu HB; Li HS Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472 [TBL] [Abstract][Full Text] [Related]
14. Dual-time point Parghane RV; Basu S Semin Nucl Med; 2017 Jul; 47(4):373-391. PubMed ID: 28583277 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography in predicting World Health Organization grade in pancreatic neuroendocrine tumors. Tomimaru Y; Eguchi H; Tatsumi M; Kim T; Hama N; Wada H; Kawamoto K; Kobayashi S; Morii E; Mori M; Doki Y; Nagano H Surgery; 2015 Feb; 157(2):269-76. PubMed ID: 25311263 [TBL] [Abstract][Full Text] [Related]
16. Differentiation and diagnosis of benign and malignant testicular lesions using 18F-FDG PET/CT. Shao D; Gao Q; Tian XW; Wang SY; Liang CH; Wang SX Eur J Radiol; 2017 Aug; 93():114-120. PubMed ID: 28668404 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of soft-tissue lesions with (18)F-FDG PET/CT: initial results of a prospective trial. Leal AL; Etchebehere M; Santos AO; Kalaf G; Pacheco EB; Amstalden EM; Etchebehere EC Nucl Med Commun; 2014 Mar; 35(3):252-9. PubMed ID: 24300379 [TBL] [Abstract][Full Text] [Related]
18. Diagnostic value and limitations of fluorine-18 fluorodeoxyglucose positron emission tomography for cartilaginous tumors of bone. Lee FY; Yu J; Chang SS; Fawwaz R; Parisien MV J Bone Joint Surg Am; 2004 Dec; 86(12):2677-85. PubMed ID: 15590853 [TBL] [Abstract][Full Text] [Related]
19. Role of Combined 68Ga-DOTATOC and 18F-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors: Implications for Managing Surgical Decisions. Cingarlini S; Ortolani S; Salgarello M; Butturini G; Malpaga A; Malfatti V; DʼOnofrio M; Davì MV; Vallerio P; Ruzzenente A; Capelli P; Citton E; Grego E; Trentin C; De Robertis R; Scarpa A; Bassi C; Tortora G Pancreas; 2017 Jan; 46(1):42-47. PubMed ID: 27906872 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma. Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]